Thomas Grace, MD
Family Medicine · Findlay, OHNPI 1295047298
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $430,790 of the $503,109 with a category attached, or 85.6%. 12 manufacturers reported payments, led by Dexcom, Inc. at 43.1% of the total. Among family medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 729 payments — averaging $690.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$217K
- Lilly USA, LLC$164K
- Novo Nordisk$105K
- Sanofi-aventis U.S. LLC$10K
- Insulet Corporation$3K
- Eli Lilly$2K
- plus $2K from 6 others
Across 16 payments — averaging $52,302 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$837K
What the payments were for
- Consulting fees$27,0525%
- Speaking & faculty fees$430,79086%
- Travel & lodging$34,1447%
- Food & beverage$11,0752%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 239 | $216,688 |
| Lilly USA, LLC | 252 | $164,403 |
| Novo Nordisk | 181 | $105,069 |
| Sanofi-aventis U.S. LLC | 27 | $9,843 |
| Insulet Corporation | 8 | $3,321 |
| Eli Lilly | 1 | $1,875 |
| Tandem Diabetes Care, Inc. | 5 | $1,256 |
| Abbott | 11 | $381 |
| Bayer | 1 | $125 |
| Boehringer Ingelheim | 2 | $118 |
| Johnson & Johnson | 1 | $18 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$110,825
- DEXCOM G7 GSS (161)$104,586
- DEXCOM G6 TRANSMITTER$94,437
- RYBELSUS$63,316
- Ozempic$30,825
- LYUMJEV$25,950
- DEXCOM G6 CGM SYSTEM$13,800
- TOUJEO$4,997
- SOLIQUA 100/33$4,116
- Omnipod$3,280
- t-slim insulin pump$1,121
- MOUNJARO$125
- Kerendia$125
- FreeStyle Libre Pro$125
- t:slim X2 Insulin Pump with Control-IQ$116
- FREESTYLE LIBRE 3$106
- JARDIANCE$103
How this compares
$503,109 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 370 | $454,199 |
| JardianceEmpagliflozin | 386 | $386,159 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 114 | $193,021 |
| MounjaroTirzepatide | 137 | $164,126 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 120 | $124,999 |
| TrulicityDulaglutide | 78 | $80,814 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $59,239 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 71 | $47,915 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 68 | $47,058 |
| FarxigaDapagliflozin Propanediol | 36 | $40,079 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $32,948 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $31,525 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 22 | $27,525 |
| Humalog Kwikpen U-100Insulin Lispro | 53 | $23,803 |
| Novolog FlexpenInsulin Aspart | 63 | $23,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $105,069 | $454,199370 claims |
| Boehringer IngelheimJardiance | $118 | $386,159386 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $164,403 | $246,492237 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $9,843 | $130,373148 claims |
| AstraZenecaFarxiga | $11 | $40,07936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Findlay
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
- David NeidhardtLima$248K
- Paul HanahanPainesville$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.